HCWB — HCW Biologics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828673 ·
Last close
$1.93
Market Cap
$3.54M
52W High
$29.28
52W Low
$1.50
ADV30
729,727
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 135,568 | -93,887 | -3,151,876 | -5,219,231 | 26,768,318 | 741,324 | 19,340,704 |
| Mar 2026 | 6,543,001 | 6,531,930 | 3,250,122 | 3,472,480 | 27,342,213 | 1,228,879 | 21,579,779 |
| Dec 2025 | 27,010 | 5,401 | -2,947,409 | 719,232 | 24,520,013 | 1,952,464 | 21,755,244 |
| Sep 2025 | 15,606 | 3,121 | -3,276,624 | -4,554,336 | 25,445,540 | 1,096,909 | 27,552,737 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,452,987
Investing CF
$0
Financing CF
$11,574,253
CapEx
$-113,412
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-21.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-105,043,366
Inventory
—
Receivables
$74,844
ST Investments
—
EBIT TTM
$-1,136,406
Pretax Income TTM
$-1,960,168
Interest Exp TTM
$823,762
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,721,186
EBITDA
$-5,584,538
Free Cash Flow
$-11,661,168
Enterprise Value
$9,933,403
Total Cash
$741,324
Total Debt
$6,561,361
Shares Out
1,836,324
Trailing EPS
$-16.62
Book Value
$4.59
ROE
-151.4%
ROA
-13.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 54,232 | -11,257,288 | -7,959,709 | 24,520,013 | 21,755,244 | 2,764,769 | -13,391,617 |
| Dec 2024 | 2,566,792 | -27,629,216 | -30,023,814 | 30,236,578 | 37,006,750 | -6,770,172 | -14,227,428 |
| Dec 2023 | 2,841,794 | -25,717,160 | -24,994,277 | 28,513,660 | 15,051,943 | 13,461,717 | -22,514,121 |
| Dec 2022 | 6,722,090 | -15,078,778 | -14,900,703 | 46,809,155 | 9,380,649 | 37,428,506 | -10,386,110 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JUNS | JUPITER NEUROSCIENCES, INC. | $3.52M | $2.67 | — |
| MBIO | MUSTANG BIO, INC. | $3.50M | $0.52 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $3.47M | $0.87 | — |
| APVO | Aptevo Therapeutics Inc. | $3.42M | $1.89 | — |
| PRFX | PRF Technologies Ltd. | $3.42M | $0.98 | — |
News headlines (Yahoo Finance, 1h cache)
HCW Biologics Announces Pricing of $1.5 Million Private Placement
2026-09-24 12:25 · Yahoo
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent
2026-09-08 13:49 · Yahoo
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
2026-09-08 12:50 · Yahoo
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
2026-09-02 13:00 · Yahoo
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
2026-08-25 13:00 · Yahoo
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
2026-06-30 12:25 · Yahoo
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
2026-06-26 12:55 · Yahoo
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
2026-06-16 11:00 · Yahoo
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
2026-05-22 20:02 · Yahoo
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
2026-05-21 13:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.